Form 4: Cidara Therapeutics Executive Receives Stock Options and Restricted Stock Units

Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, acquires stock options and restricted stock units (RSUs) as part of compensation.

Summary

• On May 1, 2025, Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, received 10,000 Restricted Stock Units (RSUs) and options to purchase 20,000 shares of common stock.
• The RSUs vest in three equal annual installments starting June 10, 2026, contingent upon continuous service.
• The stock options vest in 36 equal monthly installments from May 1, 2025, also subject to continuous service.
• The exercise price for the stock options is $21.75, and they expire on April 30, 2035.
• Following these transactions, Davarpanah directly owns 31,692 shares of Cidara Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest an expectation of continued employment and contribution from the executive.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The specific terms of the grants (vesting schedule, exercise price) are typical for the industry.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include a mix of salary, stock options, and restricted stock units.
• Companies like Amgen, Gilead, and Biogen also use similar compensation structures to incentivize their executives.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with shareholder value creation.
• Employees: The grant may serve as a positive signal regarding the company's commitment to its leadership team.

Key Dates

Keywords

Cidara Therapeutics, stock options, RSUs, insider trading, executive compensation, beneficial ownership, Form 4, Davarpanah, CDTX